This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Zacks.com on MSN17h
3 Stocks Seeing Insider Buys: CNC, PFE, BMYInvestors closely monitor insider buys, as they can give hints surrounding the long-term picture. An insider is an officer, ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...
Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...
Zacks.com on MSN1d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback